ACHE and early-onset autosomal dominant Alzheimer disease: Though adverse reactions caused by AChE‐Fc administration has not been reported, acetylcholine deficiency caused by heightened AChE activity has been reported to have a potential physiological response that may lead to cognitive impairment as observed in Alzheimer disease models with acetylcholine deficiency.15, 16, 17